1. Home
  2. RYTM vs AEIS Comparison

RYTM vs AEIS Comparison

Compare RYTM & AEIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • AEIS
  • Stock Information
  • Founded
  • RYTM 2008
  • AEIS 1981
  • Country
  • RYTM United States
  • AEIS United States
  • Employees
  • RYTM N/A
  • AEIS N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • AEIS Industrial Machinery/Components
  • Sector
  • RYTM Health Care
  • AEIS Technology
  • Exchange
  • RYTM Nasdaq
  • AEIS Nasdaq
  • Market Cap
  • RYTM 5.9B
  • AEIS 4.7B
  • IPO Year
  • RYTM 2017
  • AEIS 1995
  • Fundamental
  • Price
  • RYTM $88.64
  • AEIS $142.99
  • Analyst Decision
  • RYTM Strong Buy
  • AEIS Buy
  • Analyst Count
  • RYTM 13
  • AEIS 9
  • Target Price
  • RYTM $89.77
  • AEIS $129.11
  • AVG Volume (30 Days)
  • RYTM 1.0M
  • AEIS 349.7K
  • Earning Date
  • RYTM 08-05-2025
  • AEIS 08-05-2025
  • Dividend Yield
  • RYTM N/A
  • AEIS 0.28%
  • EPS Growth
  • RYTM N/A
  • AEIS N/A
  • EPS
  • RYTM N/A
  • AEIS 1.94
  • Revenue
  • RYTM $136,863,000.00
  • AEIS $1,559,142,000.00
  • Revenue This Year
  • RYTM $37.47
  • AEIS $15.58
  • Revenue Next Year
  • RYTM $71.16
  • AEIS $7.71
  • P/E Ratio
  • RYTM N/A
  • AEIS $72.70
  • Revenue Growth
  • RYTM 48.88
  • AEIS 0.06
  • 52 Week Low
  • RYTM $40.61
  • AEIS $75.01
  • 52 Week High
  • RYTM $94.80
  • AEIS $145.52
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 71.18
  • AEIS 64.10
  • Support Level
  • RYTM $87.86
  • AEIS $139.44
  • Resistance Level
  • RYTM $92.14
  • AEIS $145.52
  • Average True Range (ATR)
  • RYTM 3.57
  • AEIS 3.48
  • MACD
  • RYTM 1.01
  • AEIS -0.51
  • Stochastic Oscillator
  • RYTM 77.38
  • AEIS 65.84

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About AEIS Advanced Energy Industries Inc.

Advanced Energy Industries Inc provides precision power-conversion measurement and control solutions that transform power into various forms for use in manufacturing and industrial equipment and applications. The firm serves original equipment manufacturers and end customers in the semiconductor, flat panel display, solar panel, and other industrial capital equipment markets. Products include thin-film power-conversion systems, which control and modify raw electrical power into a customizable, predictable power source, and power control modules, which control and measure temperature during manufacturing cycles. A majority of the firm's revenue is generated in United States, with the rest from Mexico, Taiwan, China and All others.

Share on Social Networks: